Dr. Hofmeister is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1365 Clifton Rd NE
Atlanta, GA 30322Phone+1 404-778-8580Fax+1 404-778-1215
Summary
- I am a hematologist specializing in patients with multiple myeloma.
Education & Training
- Ohio State UniversityMPH, Clinical Investigation, 2009 - 2012
- Loyola University Medical CenterFellowship, Hematopoietic Stem Cell Transplantation, 2005 - 2006
- Loyola University Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
- Loyola University Medical CenterResidency, Internal Medicine, 1999 - 2002
- Ohio State University College of MedicineClass of 1999
- Brown UniversityBS, Biochemistry and Molecular Biology, 1991 - 1995
Certifications & Licensure
- GA State Medical License 2017 - 2025
- LA State Medical License 2020 - 2022
- NC State Medical License 2020 - 2022
- AL State Medical License 2020 - 2020
- OH State Medical License 2006 - 2018
- IL State Medical License 1999 - 2008
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Business First’s Forty Under 40 Award Columbus Dispatch, 2011
- Early Career Achievement Award The Ohio State University College of Medicine, 2011
- Imagine MMORE Award MMORE (Multiple Myeloma Opportunities for Research & Education), 2009
- Join now to see all
Clinical Trials
- Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma Start of enrollment: 2004 Jul 01
- Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease Start of enrollment: 2003 Jul 01
- Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation Start of enrollment: 2004 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 633 citationsThe PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibodyDon M. Benson, Courtney E. Bakan, Anjali Mishra, Craig C. Hofmeister, Yvonne A. Efebera
Blood. 2010-09-30 - 336 citationsCS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myelomaJianhong Chu, Youcai Deng, Don M. Benson, Shun He, Tiffany Hughes
Leukemia. 2014-04-01 - 120 citationsGain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.Timothy M. Schmidt, Benjamin G. Barwick, Nisha Joseph, Leonard T. Heffner, Craig C. Hofmeister
Blood Cancer Journal. 2019-11-25
Journal Articles
- Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple MyelomaMyo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
- Evidence Does Not Support Clinically Significant Lenalidomide-CCI-779 Interaction via P-Glycoprotein ReplyHofmeister,CC; Yang,X; Phelps,MA, Journal of Clinical Oncology, 1/1/2012
- Evaluation of pulmonary infiltrates in post stem cell transplant patientsScaglione S, Hofmeister CC, Stiff PJ, Hematology, 12/1/2005
- Join now to see all
Abstracts/Posters
- Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with ...Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple MyelomaCraig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- When Is Treating a Precursor Condition Harmful?October 8th, 2024
- Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual MeetingMay 29th, 2020
- Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational HighlightsMarch 5th, 2020
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: